Calidi Biotherapeutics Inc. Featured in NetworkNewsWire Spotlight on Genetic Medicines
July 11th, 2025 1:05 PM
By: Newsworthy Staff
Calidi Biotherapeutics Inc. (NYSE American: CLDI) is highlighted in a NetworkNewsWire editorial for its innovative approach to treating hard-to-treat cancers with systemic genetic medicines, showcasing its potential to transform oncology and autoimmune disorder treatments.
Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company, has been featured in a NetworkNewsWire editorial titled 'Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers.' The article sheds light on Calidi's pioneering platform that employs engineered viruses to deliver genetic therapies directly to tumors, marking a significant advancement in the treatment of primary and metastatic cancers. While the company's initial focus is on oncology, it is also exploring the platform's applications in autoimmune disorders, indicating its wide-ranging therapeutic potential. This development is particularly noteworthy given the increasing global cancer burden and the urgent need for innovative treatment solutions. The editorial underscores Calidi's contribution to the field of genetic medicines and its role in pushing the boundaries of cancer treatment. For more details, visit https://ibn.fm/18sdm.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
